Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis

BACKGROUND: Multiple sclerosis is the most common demyelinating disease of the central nervous system with serious social and economic burden. Siponimod is a sphingosine-1-phosphate receptor agonist, and clinical trials in the past decade have shown good prospects for the treatment of multiple scler...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yumeng, Lao, Yongfeng, Liang, Fuxiang, Li, Jing, Jia, Bibo, Wang, Zixuan, Hui, Xu, Lu, Zhenxing, Zhou, Biao, Luo, Wei, Song, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716697/
https://www.ncbi.nlm.nih.gov/pubmed/31441835
http://dx.doi.org/10.1097/MD.0000000000015415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716697/
https://www.ncbi.nlm.nih.gov/pubmed/31441835
http://dx.doi.org/10.1097/MD.0000000000015415

Ejemplares similares